ClinicalTrials.gg
TerminatedNCT02052635NSTE-ACSUpdated May 27, 2016Results posted

Ticagrelor vs Clopidogrel in Non-ST Elevation Acute Coronary Syndrome Patients Undergoing PCI With Bivalirudin.

A Phase 4 interventional study of ticagrelor and clopidogrel in Non-ST Elevation Acute Coronary Syndrome, sponsored by AstraZeneca. Terminated at 8 sites in United States. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2016-05-27.

Sponsored by AstraZeneca · Phase 4, Interventional, and Treatment

Why this study was terminated
Patient recruitment challenges, low enrolment, and a forecasted inability to complete the study in an acceptable timeframe

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing ticagrelor in Acute Coronary Syndrome — 6 open to participants now, 8 under way, 1 of them phase 3. Ticagrelor · Acute Coronary Syndrome.

Enrollment
62nd of 67
34 · median 120
Started
2014
with 12 others
Phase 4
38 of 67
5 open now
Registered
21st of 67
by date
Lead sponsor
8 of 67
AstraZeneca

Among the 67 studies testing ticagrelor in Acute Coronary Syndrome, this one is the 62nd largest by enrollment, is one of 13 that started in 2014, is one of 38 in phase 4, and was the 21st registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

6 of the 67 studies testing ticagrelor in Acute Coronary Syndrome are open now, in 7 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing ticagrelor in Acute Coronary Syndrome, or all of them as a file.
02

Study summary

The purpose of this study is to determine if ticagrelor is as effective as clopidogrel in rate of onset and degree of platelet inhibition for patients with non-ST elevation of acute coronary syndrome (NSTE-ACS) undergoing ad hoc percutaneous coronary intervention (PCI) with bivalirudin.

Read the detailed description

Multi-center, open-label study that will compare the onset of the platelet inhibition with ticagrelor versus clopidogrel when administered with bivalirudin during PCI on a background therapy of aspirin in patients with NSTE-ACS.

03

Conditions studied

  • Non-ST Elevation Acute Coronary Syndrome

Keywords

  • Percutaneous Coronary Intervention
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hospitalised for chest pain and potential acute coronary syndrome.
  • Onset of the most recent cardiac ischemic symptoms must occur within 7 days before randomisation and documented by cardiac ischemic symptoms of ≥ 10 min duration at rest and at least 2 of the following: ST segment changes on (ECG) indicative of ischemia, or Positive biomarker evdience of myocardial necrosis, or other risk factors such as: 60 yrs of age or older, previous myocardial infarction or coronary bypass surgery, multi-vessel coronary artery disease, diabetes mellitus, peripheral arterial disease, chronic renal disfunction.
  • Females must be either surgically sterile or .
  • Activated Clotting Time (ACT) \</= 300 at the time of study treatment

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical study with an product during the last 30 days.
  • Current acute complication of percutaneous coronary intervention or coronary bypass surgery.
  • Any to ticagrelor, clopidogrel or bivalirudin.
  • ST elevation myocardial infraction within 24 hours of study entry.
  • Any indications for oral anticoagulation or aspirin dose other than 75 to 100 milligrams (mg) daily.
  • Planned use of omeprazole or esomeprazole.
  • Patients with known bleeding or coagulation disorders; patients requiring dialysis; patients who have an inability to swallow medication.
  • Patients with known bleeding diathesis or coagulation disorder; history of intracranial bleed.
  • Use of Intravenous (IV) heparin less than 2 hours before procedure.
  • Sustained uncontrolled high blood pressure
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (actual)

Study arms

  • Experimental
    Ticagrelor

    90 mg oral tablet

    Drug: ticagrelor

  • Active comparator
    Clopidogrel

    300 mg oral tablet

    Drug: clopidogrel

Interventions

  • Single loading dose of 180mg of ticagrelor at time of bivalirudin administration. Beginning 12 hrs following study drug administration, all pts in the ticagrelor arm will receive ticagrelor 90 mg (maintenance dose) approximately every 12 hrs until Follow-up telephone contact.

    Also known as: Brilinta

  • Single loading oral dose of 600 mg of clopidogrel will be given at time of bivalirudin administration. Beginning 4 hrs following study drug administration, all pts in the clopidorgrel arm will receive ticagrelor 180 mg for the loading dose, followed by 90 mg maintenance dose approximately every 12 hours until the Follow-up telephone contact.

    Also known as: Plavix

06

What researchers measure

Primary outcomes

  1. P2Y12 Reaction Units (PRU) Using VerifyNow™ at 0.5 Hours After Loading Dose

    PRU at 0.5 hours after a single oral loading dose of either ticagrelor 180 mg or clopidogrel 600 mg given at the time of the bivalirudin bolus

    Time frame: 0.5 hours post loading dose

  2. P2Y12 Reaction Units (PRU) Using VerifyNow™ at 1 Hour After Loading Dose

    PRU at 1 hour after a single oral loading dose of either ticagrelor 180 mg or clopidogrel 600 mg given at the time of the bivalirudin bolus

    Time frame: 1 hour post loading dose

07

Results

Posted Apr 6, 2016
Limitations and caveats
The target sample size for this study was 100 patients. But due to recruitment challenges and low enrolment,the study was terminated early with only 13 pateints randomized. No formal statistical analyses were performed.

Participant flow

This study was conducted in the USA. While 17 sites were activated, 9 sites enrolled patients, and only 7 sites successfully randomised patients. There were 34 patients screened, 21 screen failures and 13 randomised patients from 03 September 2014 and 20 April 2015. The study was terminated due to recruitment challenges and low enrolment concerns.

Participant flow — Overall Study
MilestoneTicagrelorClopidogrel
Started76
Completed76
Not completed00

Outcome measures

PrimaryP2Y12 Reaction Units (PRU) Using VerifyNow™ at 0.5 Hours After Loading Dose

PRU at 0.5 hours after a single oral loading dose of either ticagrelor 180 mg or clopidogrel 600 mg given at the time of the bivalirudin bolus

Time frame:
0.5 hours post loading dose
Reported as:
Mean · PRUs
P2Y12 Reaction Units (PRU) Using VerifyNow™ at 0.5 Hours After Loading Dose
PRUsTicagrelorClopidogrel
P2Y12 Reaction Units (PRU) Using VerifyNow™ at 0.5 Hours After Loading Dose289.2 ± 44.6292.8 ± 38.7
PrimaryP2Y12 Reaction Units (PRU) Using VerifyNow™ at 1 Hour After Loading Dose

PRU at 1 hour after a single oral loading dose of either ticagrelor 180 mg or clopidogrel 600 mg given at the time of the bivalirudin bolus

Time frame:
1 hour post loading dose
Reported as:
Mean · PRUs
P2Y12 Reaction Units (PRU) Using VerifyNow™ at 1 Hour After Loading Dose
PRUsTicagrelorClopidogrel
P2Y12 Reaction Units (PRU) Using VerifyNow™ at 1 Hour After Loading Dose174.4 ± 88.9249.8 ± 68.7

Adverse events

Collected over Serious adverse events (SAEs) from informed consent to follow-up contact (4-7 days after treatment) and non-serious adverse events (AEs) of interest from time of randomisation to follow-up. All SAEs and non-serious AEs of interest will be recorded.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ticagrelor—0/7 (0%)2/7 (28.6%)
Clopidogrel—0/6 (0%)2/6 (33.3%)
Most frequent other events
Most frequent other events
EventTicagrelorClopidogrel
EpistaxisRespiratory, thoracic and mediastinal disorders0/71/6
HaematomaVascular disorders0/71/6
Coronary artery perforationCardiac disorders1/70/6
HaemoptysisRespiratory, thoracic and mediastinal disorders1/70/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)TicagrelorClopidogrelTotal
Mean63.9 ± 2.761.2 ± 14.762.6 ± 9.8
Sex: Female, Male
Sex: Female, Male(Participants)TicagrelorClopidogrelTotal
Female325
Male448
08

Study locations

8 sites
  • Research Site
    Jacksonville, Florida, United States
  • Research Site
    Lake Mary, Florida, United States
  • Research Site
    Macon, Georgia, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Hershey, Pennsylvania, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Pittsburgh, Pennsylvania, United States
  • Research Site
    Rapid City, South Dakota, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2016, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2014
First posted
Feb 3, 2014
Start
Sep 2014
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
Apr 6, 2016
Last update
May 27, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02052635
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 3, 2014
Start date
Sep 2014
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Apr 6, 2016
Last update
May 27, 2016

Study contacts

Marc Cohen, MD
principal investigator · Newark Beth Israel Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion